{ "schemaVersion": 1, "organisationId": "O-4f30227d383f426a905024dc866365d2", "slug": "gsk-gsk-us", "name": "GSK plc", "updatedAt": "2026-09-28T11:45:58.619891Z", "sections": [ { "type": "OVERVIEW", "text": "GSK plc is a global biopharmaceutical company that develops and supplies vaccines and medicines. Its portfolio spans specialty medicines, vaccines and general medicines, with research focused on respiratory disease, immunology and inflammation, oncology, HIV and infectious diseases. GSK states its purpose as uniting science, technology and talent to get ahead of disease together. [https://www.gsk.com/en-gb/company/purpose-strategy-and-culture/][https://www.gsk.com/en-gb/products/]\n\nGSK operates in more than 75 countries and employed an average of approximately 68,300 people in 2025. It reported £32.7 billion in sales that year. The 2022 separation of its consumer-health business into Haleon established GSK’s current focus on biopharmaceuticals. [https://archive.legmt.gov/content/Committees/Interim/2025-2026/EAIC/October_02_2025/GSK_Presentation.pdf][https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/R118.htm][https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/][https://www.gsk.com/en-gb/media/press-releases/completion-of-the-demerger-of-haleon-and-share-consolidation-of-gsk/]\n[T17448640][https://www.gsk.com/en-gb/company/purpose-strategy-and-culture/][https://www.gsk.com/en-gb/products/][https://archive.legmt.gov/content/Committees/Interim/2025-2026/EAIC/October_02_2025/GSK_Presentation.pdf][https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/R118.htm][https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/][https://www.gsk.com/en-gb/media/press-releases/completion-of-the-demerger-of-haleon-and-share-consolidation-of-gsk/]", "updatedAt": "2026-09-28T11:45:58.619891Z" }, { "type": "PRODUCTS", "text": "GSK’s products fall into three groups: vaccines, specialty medicines and general medicines. In 2025, they generated approximately £9.2 billion (28%), £13.5 billion (41%) and £10.0 billion (31%) of sales, respectively; the percentages are calculated from GSK’s rounded figures. [https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/]\n\nIts vaccines include Shingrix, a recombinant, adjuvanted vaccine to prevent shingles; Arexvy, an adjuvanted vaccine to prevent respiratory syncytial virus (RSV) lower respiratory tract disease; and meningococcal vaccines Bexsero, Menveo and Penmenvy. Penmenvy targets meningococcal groups A, B, C, W and Y. Shingrix generated approximately £3.6 billion in 2025 sales, making it one of GSK’s largest individual products. [https://www.gsk.com/en-gb/products/products-a-z/][https://us.gsk.com/en-us/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/][https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/]\n\nSpecialty medicines span HIV, respiratory and inflammatory disease, and oncology. The HIV portfolio includes Dovato, a two-drug oral HIV-1 treatment; Cabenuva, a long-acting injectable HIV-1 treatment for eligible patients whose virus is suppressed; and Apretude, a long-acting injectable for HIV prevention. Other products include Nucala (mepolizumab), an IL-5-targeting treatment for eosinophilic diseases; Benlysta (belimumab) for lupus and lupus nephritis; Jemperli (dostarlimab) for certain endometrial cancers; and Ojjaara (momelotinib) for myelofibrosis with anemia. HIV medicines generated approximately £7.7 billion in 2025 sales. [https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-dovato-for-adolescents-living-with-hiv/][https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-for-virologically-suppressed-adolescents-living-with-hiv-who-are-12-years-of-age-or-older-and-weigh-at-least-35-kg/][https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-apretude-cabotegravir-extended-release-injectable-suspension-the-first-and-only-long-acting-injectable-option-for-hiv-prevention/][https://www.gsk.com/en-gb/products/products-a-z/][https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/]\n\nGeneral medicines include respiratory inhalers and antibiotics. Trelegy Ellipta combines an inhaled corticosteroid and two bronchodilators in a once-daily inhaler for maintenance treatment of chronic obstructive pulmonary disease (COPD) or asthma in adults; other respiratory brands include Anoro Ellipta and Ventolin. Trelegy generated approximately £3.0 billion in 2025 sales. GSK also offers product-specific patient assistance and reimbursement support in certain markets; availability and eligibility vary by country. [https://us.gsk.com/en-us/media/press-releases/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us/][https://www.gsk.com/en-gb/products/our-product-areas/][https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/][https://gskpro.com/en-us/resources/patient-assistance/]\n[https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/][https://www.gsk.com/en-gb/products/products-a-z/][https://us.gsk.com/en-us/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/][https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-dovato-for-adolescents-living-with-hiv/][https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-for-virologically-suppressed-adolescents-living-with-hiv-who-are-12-years-of-age-or-older-and-weigh-at-least-35-kg/][https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-apretude-cabotegravir-extended-release-injectable-suspension-the-first-and-only-long-acting-injectable-option-for-hiv-prevention/][https://us.gsk.com/en-us/media/press-releases/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us/][https://www.gsk.com/en-gb/products/our-product-areas/][https://gskpro.com/en-us/resources/patient-assistance/]", "updatedAt": "2026-09-28T11:45:58.619891Z" }, { "type": "GEOGRAPHY", "text": "GSK plc is headquartered in London and operates in 70 countries. Its global footprint includes 33 manufacturing sites and approximately 66,800 employees. Its principal research and development hubs are in the UK, US and Belgium, within a wider R&D network spanning Europe, North America and Asia. [https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm][https://www.gsk.com/en-gb/company/gsk-at-a-glance/][https://www.gsk.com/en-gb/innovation/rd-locations/]\n\nIn 2025, GSK reported £32.7 billion in turnover by customer location. The US accounted for £16.9 billion, or about 52% of the total; International markets for £8.3 billion, or 25%; Europe for £6.9 billion, or 21%; and the UK, reported separately from Europe, for £0.7 billion, or 2%. [https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/R105.htm]\n[https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm][https://www.gsk.com/en-gb/company/gsk-at-a-glance/][https://www.gsk.com/en-gb/innovation/rd-locations/][https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/R105.htm][https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm][https://www.gsk.com/en-gb/company/gsk-at-a-glance/][https://www.gsk.com/en-gb/innovation/rd-locations/][https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/R105.htm]", "updatedAt": "2026-09-28T11:45:58.619891Z" }, { "type": "SEGMENTS", "text": "GSK reports two operating segments: Commercial Operations and Total R&D. Commercial Operations contains product sales, while Total R&D covers research and development across the business, including work on specialty medicines and vaccines; it does not have a separately reported share of turnover. [P151797284][P151797289][P151797295]\n\nWithin Commercial Operations, GSK reports three product groups. Specialty Medicines covers HIV, respiratory, immunology and inflammation, and oncology treatments; its 2025 sales were £13.5 billion, approximately 41% of turnover. Vaccines includes shingles, meningitis, RSV, influenza and established vaccines; sales were £9.2 billion, or approximately 28%. General Medicines comprises respiratory and other established medicines; sales were £10.0 billion, or approximately 31%. These are product-sales categories, not additional operating segments. [T6898399][P151797295]\n[P151797284][P151797289][P151797295][T6898399][T6898399][T6898399][T6898399]", "updatedAt": "2026-09-28T11:45:58.619891Z" }, { "type": "HISTORY", "text": "GSK’s roots lie in several pharmaceutical businesses. Silvanus Bevan opened the Plough Court pharmacy in London in 1715; John K. Smith opened a drugstore in Philadelphia in 1830; Thomas Beecham began selling Beecham’s Pills in England in 1842; and Burroughs Wellcome was established in 1880. These businesses became part of the corporate lineages that eventually formed GSK. [https://www.gsk.com/en-gb/company/history-and-heritage/][https://fr.gsk.com/media/da0dgjfg/cmyk_final_300yrs-gsk-a3-landscape.pdf]\n\nNotable medicines from those predecessor companies included the asthma treatment Ventolin, launched in 1969, and Burroughs Wellcome’s AZT, approved in 1987 as the first HIV/AIDS medicine. SmithKline Beecham was formed through a merger in 1989, followed by the creation of Glaxo Wellcome in 1995. The two companies merged in December 2000 to form GlaxoSmithKline. [https://www.gsk.com/en-gb/media/press-releases/gsk-s-strong-science-prominent-at-ats-2019/][https://www.gsk.com/en-gb/behind-the-science-magazine/the-40-year-fight-against-hiv/][https://www.latimes.com/archives/la-xpm-1989-07-26-fi-344-story.html][http://news.bbc.co.uk/1/hi/business/606752.stm][https://www.gsk.com/media/j1ghxkvx/annual-report-2001.pdf]\n\nIn 2015, GSK completed a transaction with Novartis that added Novartis’s vaccines business, excluding influenza, while transferring GSK’s oncology business and combining the companies’ consumer-health operations. GSK subsequently combined its consumer-health business with Pfizer’s in 2019, then separated that business as the independently listed Haleon in 2022. [https://www.gsk.com/en-gb/media/press-releases/gsk-completes-major-three-part-transaction-with-novartis/][https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/][https://www.gsk.com/en-gb/investors/corporate-actions/consumer-healthcare-demerger/]\n[https://www.gsk.com/en-gb/company/history-and-heritage/][https://fr.gsk.com/media/da0dgjfg/cmyk_final_300yrs-gsk-a3-landscape.pdf][https://www.gsk.com/en-gb/media/press-releases/gsk-s-strong-science-prominent-at-ats-2019/][https://www.gsk.com/en-gb/behind-the-science-magazine/the-40-year-fight-against-hiv/][https://www.latimes.com/archives/la-xpm-1989-07-26-fi-344-story.html][http://news.bbc.co.uk/1/hi/business/606752.stm][https://www.gsk.com/media/j1ghxkvx/annual-report-2001.pdf][https://www.gsk.com/en-gb/media/press-releases/gsk-completes-major-three-part-transaction-with-novartis/][https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/][https://www.gsk.com/en-gb/investors/corporate-actions/consumer-healthcare-demerger/][https://www.gsk.com/en-gb/company/history-and-heritage/][https://fr.gsk.com/media/da0dgjfg/cmyk_final_300yrs-gsk-a3-landscape.pdf][https://www.gsk.com/en-gb/media/press-releases/gsk-s-strong-science-prominent-at-ats-2019/][https://www.gsk.com/en-gb/behind-the-science-magazine/the-40-year-fight-against-hiv/][https://www.latimes.com/archives/la-xpm-1989-07-26-fi-344-story.html][http://news.bbc.co.uk/1/hi/business/606752.stm][https://www.gsk.com/media/j1ghxkvx/annual-report-2001.pdf][https://www.gsk.com/en-gb/media/press-releases/gsk-completes-major-three-part-transaction-with-novartis/][https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/][https://www.gsk.com/en-gb/investors/corporate-actions/consumer-healthcare-demerger/]", "updatedAt": "2026-09-28T11:45:58.619891Z" } ], "sources": [ { "id": "https://www.gsk.com/en-gb/company/purpose-strategy-and-culture/", "href": "https://www.gsk.com/en-gb/company/purpose-strategy-and-culture/", "label": "www.gsk.com" }, { "id": "https://www.gsk.com/en-gb/products/", "href": "https://www.gsk.com/en-gb/products/", "label": "www.gsk.com" }, { "id": "https://archive.legmt.gov/content/Committees/Interim/2025-2026/EAIC/October_02_2025/GSK_Presentation.pdf", "href": "https://archive.legmt.gov/content/Committees/Interim/2025-2026/EAIC/October_02_2025/GSK_Presentation.pdf", "label": "archive.legmt.gov" }, { "id": "https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/R118.htm", "href": "https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/R118.htm", "label": "www.sec.gov" }, { "id": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/", "href": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/", "label": "www.gsk.com" }, { "id": "https://www.gsk.com/en-gb/media/press-releases/completion-of-the-demerger-of-haleon-and-share-consolidation-of-gsk/", "href": "https://www.gsk.com/en-gb/media/press-releases/completion-of-the-demerger-of-haleon-and-share-consolidation-of-gsk/", "label": "www.gsk.com" }, { "id": "T17448640", "href": "https://app.finbar.com/go?id=T17448640", "label": "GSK plc — Full financial report (2025 Y)", "documentId": "D-2217978d26ed42808ceff57d5a3a2a60" }, { "id": "https://www.gsk.com/en-gb/products/products-a-z/", "href": "https://www.gsk.com/en-gb/products/products-a-z/", "label": "www.gsk.com" }, { "id": "https://us.gsk.com/en-us/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/", "href": "https://us.gsk.com/en-us/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/", "label": "us.gsk.com" }, { "id": "https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-dovato-for-adolescents-living-with-hiv/", "href": "https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-dovato-for-adolescents-living-with-hiv/", "label": "us.gsk.com" }, { "id": "https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-for-virologically-suppressed-adolescents-living-with-hiv-who-are-12-years-of-age-or-older-and-weigh-at-least-35-kg/", "href": "https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-for-virologically-suppressed-adolescents-living-with-hiv-who-are-12-years-of-age-or-older-and-weigh-at-least-35-kg/", "label": "us.gsk.com" }, { "id": "https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-apretude-cabotegravir-extended-release-injectable-suspension-the-first-and-only-long-acting-injectable-option-for-hiv-prevention/", "href": "https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-apretude-cabotegravir-extended-release-injectable-suspension-the-first-and-only-long-acting-injectable-option-for-hiv-prevention/", "label": "us.gsk.com" }, { "id": "https://us.gsk.com/en-us/media/press-releases/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us/", "href": "https://us.gsk.com/en-us/media/press-releases/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us/", "label": "us.gsk.com" }, { "id": "https://www.gsk.com/en-gb/products/our-product-areas/", "href": "https://www.gsk.com/en-gb/products/our-product-areas/", "label": "www.gsk.com" }, { "id": "https://gskpro.com/en-us/resources/patient-assistance/", "href": "https://gskpro.com/en-us/resources/patient-assistance/", "label": "gskpro.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm", "href": "https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm", "label": "www.sec.gov" }, { "id": "https://www.gsk.com/en-gb/company/gsk-at-a-glance/", "href": "https://www.gsk.com/en-gb/company/gsk-at-a-glance/", "label": "www.gsk.com" }, { "id": "https://www.gsk.com/en-gb/innovation/rd-locations/", "href": "https://www.gsk.com/en-gb/innovation/rd-locations/", "label": "www.gsk.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/R105.htm", "href": "https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/R105.htm", "label": "www.sec.gov" }, { "id": "P151797284", "href": "https://app.finbar.com/go?id=P151797284", "label": "GSK plc — Full financial report (2025 Y)", "documentId": "D-2217978d26ed42808ceff57d5a3a2a60" }, { "id": "P151797289", "href": "https://app.finbar.com/go?id=P151797289", "label": "GSK plc — Full financial report (2025 Y)", "documentId": "D-2217978d26ed42808ceff57d5a3a2a60" }, { "id": "P151797295", "href": "https://app.finbar.com/go?id=P151797295", "label": "GSK plc — Full financial report (2025 Y)", "documentId": "D-2217978d26ed42808ceff57d5a3a2a60" }, { "id": "T6898399", "href": "https://app.finbar.com/go?id=T6898399", "label": "GSK — Full financial report (2025 Y), p203", "documentId": "D-93760deb789d45a8963a677c9a04131c", "page": 203 }, { "id": "https://www.gsk.com/en-gb/company/history-and-heritage/", "href": "https://www.gsk.com/en-gb/company/history-and-heritage/", "label": "www.gsk.com" }, { "id": "https://fr.gsk.com/media/da0dgjfg/cmyk_final_300yrs-gsk-a3-landscape.pdf", "href": "https://fr.gsk.com/media/da0dgjfg/cmyk_final_300yrs-gsk-a3-landscape.pdf", "label": "fr.gsk.com" }, { "id": "https://www.gsk.com/en-gb/media/press-releases/gsk-s-strong-science-prominent-at-ats-2019/", "href": "https://www.gsk.com/en-gb/media/press-releases/gsk-s-strong-science-prominent-at-ats-2019/", "label": "www.gsk.com" }, { "id": "https://www.gsk.com/en-gb/behind-the-science-magazine/the-40-year-fight-against-hiv/", "href": "https://www.gsk.com/en-gb/behind-the-science-magazine/the-40-year-fight-against-hiv/", "label": "www.gsk.com" }, { "id": "https://www.latimes.com/archives/la-xpm-1989-07-26-fi-344-story.html", "href": "https://www.latimes.com/archives/la-xpm-1989-07-26-fi-344-story.html", "label": "www.latimes.com" }, { "id": "http://news.bbc.co.uk/1/hi/business/606752.stm", "href": "http://news.bbc.co.uk/1/hi/business/606752.stm", "label": "news.bbc.co.uk" }, { "id": "https://www.gsk.com/media/j1ghxkvx/annual-report-2001.pdf", "href": "https://www.gsk.com/media/j1ghxkvx/annual-report-2001.pdf", "label": "www.gsk.com" }, { "id": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-major-three-part-transaction-with-novartis/", "href": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-major-three-part-transaction-with-novartis/", "label": "www.gsk.com" }, { "id": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/", "href": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/", "label": "www.gsk.com" }, { "id": "https://www.gsk.com/en-gb/investors/corporate-actions/consumer-healthcare-demerger/", "href": "https://www.gsk.com/en-gb/investors/corporate-actions/consumer-healthcare-demerger/", "label": "www.gsk.com" } ] }